Feasibility of gastric endoscopic submucosal dissection with continuous low-dose aspirin for patients receiving dual antiplatelet therapy

World J Gastroenterol. 2019 Jan 28;25(4):457-468. doi: 10.3748/wjg.v25.i4.457.

Abstract

Background: Endoscopic submucosal dissection (ESD) for gastric neoplasms during continuous low-dose aspirin (LDA) administration is generally acceptable according to recent guidelines. This retrospective study aimed to investigate the effect of continuous LDA on the postoperative bleeding after gastric ESD in patients receiving dual antiplatelet therapy (DAPT).

Aim: To investigate the feasibility of gastric ESD with continuous LDA in patients with DAPT.

Methods: A total of 597 patients with gastric neoplasms treated with ESD between January 2010 and June 2017 were enrolled. The patients were categorized according to type of antiplatelet therapy (APT).

Results: The postoperative bleeding rate was 6.9% (41/597) in all patients. Patients were divided into the following two groups: no APT (n = 443) and APT (n = 154). APT included single-LDA (n = 95) and DAPT (LDA plus clopidogrel, n = 59) subgroups. In the single-LDA and DAPT subgroups, 56 and 39 patients were received continuous LDA, respectively. The bleeding rate with continuous single-LDA (10.7%) was similar to that with discontinuous single-LDA (10.3%) (P > 0.99). Although the bleeding rate with continuous LDA in patients receiving DAPT (23.1%) was higher than that with discontinuous LDA in patients receiving DAPT (5.0%), no significant difference was observed (P = 0.141).

Conclusion: The bleeding rate with continuous LDA in patients receiving DAPT was not statistically different from that with discontinuous LDA in patients receiving DAPT. Therefore, continuous LDA administration may be acceptable for ESD in patients receiving DAPT, although patients should be carefully monitored for possible bleeding.

Keywords: Dual antiplatelet therapy; Endoscopic submucosal dissection; Low-dose aspirin; Postoperative bleeding; Thienopyridine.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Aspirin / administration & dosage
  • Aspirin / adverse effects
  • Clopidogrel / administration & dosage
  • Clopidogrel / adverse effects
  • Endoscopic Mucosal Resection / adverse effects*
  • Endoscopic Mucosal Resection / methods
  • Feasibility Studies
  • Female
  • Gastric Mucosa / blood supply
  • Gastric Mucosa / pathology
  • Gastric Mucosa / surgery
  • Gastrointestinal Hemorrhage / epidemiology*
  • Gastrointestinal Hemorrhage / etiology
  • Gastroscopy / adverse effects
  • Gastroscopy / methods
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / standards
  • Postoperative Hemorrhage / epidemiology*
  • Postoperative Hemorrhage / etiology
  • Practice Guidelines as Topic
  • Retrospective Studies
  • Risk Factors
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*
  • Thrombosis / prevention & control*
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aspirin